Anagram Therapeutics

Develops an oral enzyme replacement therapy for exocrine pancreatic insufficiency in cystic fibrosis, pancreatic cancer and related disorders.

View on the globe

$250MEquity raised in 2025–20262025 — · 2026 $250M · 1 equity round
$250MEquity raised, all time1 equity round sourced so far
—Latest valuationnot disclosed

Rounds over time log-scaled amounts

Funding history: 1 round from 7 May 2026 to 7 May 2026, $250M equity disclosed. Earlier rounds exist but are not sourced.7 May 2026: $250M investment, $250M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yet← earlier rounds not sourcedest. 2023Q42026Q2Q3Q42027Equity round7 May 2026 · $250M investment · $250M · led by BlackstoneVenture · $250M
Funding history: 1 round from 7 May 2026 to 7 May 2026, $250M equity disclosed. Earlier rounds exist but are not sourced.7 May 2026: $250M investment, $250M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yetearlier rounds not sourced’232026Q2Q3Q42027Equity round7 May 2026 · $250M investment · $250M · led by Blackstone$250M

Funding history 1 round · 2 sources

Earlier rounds not yet sourced. Anagram Therapeutics was founded in 2023 and raised before 7 May 2026; only the rounds below are sourced so far, so its all-time equity total understates its history.

  1. $250M investment
    Amount$250M
    Post-money—
    ✓ Confirmed
    Lead
    Blackstone
    Note
    Blackstone Life Sciences (BXLS) announced a $250M investment to fund further development, approval and launch of ANG003; the release and Crunchbase News do not say whether it is equity or a structured/royalty-type financing, so it is recorded as stage venture. Earlier funding (incl. Cystic Fibrosis Foundation support) is not sourced here.
    Sources
  2. Earlier rounds not yet sourced

Investors 1

  • Blackstone1

Highlighted investors led at least one equity round; the number is equity rounds taken part in.

Related companies shared investors

Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Anagram Therapeutics and its logo are trademarks of their owners, used here for identification only.